Literature DB >> 3820216

Quinolonecarboxylic acids. 2. Synthesis and antibacterial evaluation of 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acids.

V Cecchetti, A Fravolini, R Fringuelli, G Mascellani, P Pagella, M Palmioli, G Segre, P Terni.   

Abstract

A series of pyridobenzothiazine acid derivatives was synthesized and their in vitro antibacterial activity was evaluated. The 1,4-benzothiazine intermediates, which by Gould-Jacobs quinoline synthesis produced pyridobenzothiazine acids, were prepared by hydrolytic basic cleavage of substituted 2-aminobenzothiazoles and successive cyclocondensation with 1-bromo-2-chloroethane or alternatively with monochloroacetic acid, hence reduction by LiAlH4. The pyridobenzothiazine acids 10c, 30, and 31 show potent antibacterial activities against Gram-positive and Gram-negative pathogens. Structure-activity relationships are discussed. The compound 9-fluoro-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-d e] [1,4]benzothiazine-6-carboxylic acid (31) (MF-934) has been found to possess, together with the antibacterial activity, a weak acute toxicity and interesting pharmacokinetic characteristics in several animal species (rat, dog, monkey, man).

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3820216     DOI: 10.1021/jm00386a005

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  14 in total

1.  Pharmacokinetics of rufloxacin in healthy volunteers.

Authors:  G Segre; D Cerretani; L Moltoni; R Urso
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Absence of effect of rufloxacin on theophylline pharmacokinetics in steady state.

Authors:  M Kinzig-Schippers; U Fuhr; M Cesana; C Müller; A H Staib; S Rietbrock; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

3.  Biliary excretion of rufloxacin in humans.

Authors:  G Privitera; G Nicastro; B P Imbimbo; M Cesana; M Visconti; F Lombardi; G Tagliabue; E Faleschini; F Colturani; P Franzini
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

4.  Comparative activity of the new fluoroquinolone rufloxacin (MF 934) against clinical isolates of gram-negative and gram-positive bacteria.

Authors:  S M Qadri; Y Ueno; G Postle; D Tullo; J San Pedro
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-05       Impact factor: 3.267

5.  Multiple-dose pharmacokinetics and safety of rufloxacin in normal volunteers.

Authors:  J C Kisicki; R S Griess; C L Ott; G M Cohen; R J McCormack; W M Troetel; B P Imbimbo
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

6.  High performance liquid chromatography and preliminary pharmacokinetics of rufloxacin and its metabolites N-desmethylrufloxacin and rufloxacinsulfoxide in plasma and urine of humans.

Authors:  T B Vree; M van den Biggelaar-Martea; B P Imbimbo
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Jan-Mar       Impact factor: 2.441

7.  Effects of magnesium-aluminum hydroxide antacid on absorption of rufloxacin.

Authors:  M Lazzaroni; B P Imbimbo; S Bargiggia; O Sangaletti; L Dal Bo; G Broccali; G Bianchi Porro
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

8.  Rufloxacin once daily versus ofloxacin twice daily for treatment of complicated cystitis and upper urinary tract infections. Italian Multicentre UTI Rufloxacin Group.

Authors:  R Mattina; C E Cocuzza; M Cesana
Journal:  Infection       Date:  1993 Mar-Apr       Impact factor: 3.553

9.  Pharmacokinetics of rufloxacin in patients with impaired renal function.

Authors:  G Perry; T G Mant; P J Morrison; S Sacks; J Woodcook; R Wise; B P Imbimbo
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

10.  Rufloxacin once daily in acute exacerbations of chronic bronchitis.

Authors:  M Dirksen; J Focht; J Boerema
Journal:  Infection       Date:  1991 Jul-Aug       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.